Cover Image
市場調查報告書

精神疾病:開發中產品分析

Psychosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192795
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
精神疾病:開發中產品分析 Psychosis - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 70 Pages
簡介

所謂精神病是指嚴重精神障礙,特徵是思考及感情嚴重受損,造成患者失去與現實的連結。主要的症狀有無秩序的思考·發言·行動,及思考混亂(往返於無關的話題,思考和思考之間賦與奇妙的關聯等)、緊張症(無感症)等。主要的治療方法有採用抗精神病藥來控制、也有改善思考和行動,在醫學障礙和精神障礙方面都有效用。

本報告提供全球各國治療精神疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

精神疾病概要

治療藥的開發

  • 開發中產品的概要

精神疾病:企業開發中的治療藥

精神疾病:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

精神疾病:企業開發中的產品

精神疾病的治療藥開發企業

  • Acadia Pharmaceuticals Inc.
  • Addex Therapeutics Ltd
  • Evotec AG
  • Gabather AB
  • Glenmark Pharmaceuticals Ltd.
  • Heptares Therapeutics Limited
  • Integrative Research Laboratories Sweden AB
  • Merck & Co., Inc.
  • Newron Pharmaceuticals S.p.A.
  • Reviva Pharmaceuticals Inc.
  • 大日本住友製藥
  • Sunovion Pharmaceuticals Inc.
  • Wuhan Docan Pharmaceutical Co., Ltd

精神疾病:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

精神疾病:最近的開發平台趨勢

精神疾病:暫停中的計劃

精神疾病:開發中止的產品

精神疾病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8601IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psychosis - Pipeline Review, H2 2016, provides an overview of the Psychosis (Central Nervous System) pipeline landscape.

Psychosis is a serious mental disorder characterized by thinking and emotions that are so impaired, that they indicate that the person experiencing them has lost contact with reality. Psychotic symptoms include disorganized thought, speech or behavior, disordered thinking (jumping between unrelated topics, making strange connections between thoughts), Catatonia (unresponsiveness). Treatment includes antipsychotic drugs, which reduce hallucinations and delusions and improve thinking and behavior are helpful, whether the cause is a medical or psychiatric disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psychosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Psychosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psychosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Psychosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15 and 1 respectively for Psychosis.

Psychosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psychosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Psychosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psychosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psychosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psychosis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psychosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psychosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Psychosis Overview
  • Therapeutics Development
    • Pipeline Products for Psychosis - Overview
  • Psychosis - Therapeutics under Development by Companies
  • Psychosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Psychosis - Products under Development by Companies
  • Psychosis - Companies Involved in Therapeutics Development
    • Acadia Pharmaceuticals Inc.
    • Addex Therapeutics Ltd
    • Evotec AG
    • Gabather AB
    • Glenmark Pharmaceuticals Ltd.
    • Heptares Therapeutics Limited
    • Integrative Research Laboratories Sweden AB
    • Merck & Co., Inc.
    • Newron Pharmaceuticals S.p.A.
    • Reviva Pharmaceuticals Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Sunovion Pharmaceuticals Inc.
  • Psychosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADX-88178 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CB-0306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • evenamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GT-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GT-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GT-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HUF-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRL-790 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pimavanserin tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RP-5063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEP-39 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Psychosis - Dormant Projects
  • Psychosis - Discontinued Products
  • Psychosis - Product Development Milestones
    • Featured News & Press Releases
      • May 31, 2016: ACADIA Pharmaceuticals Announces NUPLAZID (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson's Disease Psychosis
      • Apr 29, 2016: FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease
      • Mar 29, 2016: FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals' NUPLAZID(Pimavanserin) for the Treatment of Psychosis Associated with Parkinson's Disease Outweigh the Risks
      • Jan 29, 2016: ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID(Pimavanserin) for the Treatment of Parkinson's Disease Psychosis
      • Nov 17, 2014: Heptares First-In-Class Selective Muscarinic Agonists Chosen As One Of Top Neuroscience Projects To Watch
      • Sep 02, 2014: Acadia Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson's Disease Psychosis
      • Aug 28, 2014: ACADIA Pharmaceuticals Announces Trade Name NUPLAZID for Pimavanserin
      • Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting
      • Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
      • May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
      • Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Psychosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
  • Psychosis - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Psychosis - Pipeline by Evotec AG, H2 2016
  • Psychosis - Pipeline by Gabather AB, H2 2016
  • Psychosis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Psychosis - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Psychosis - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016
  • Psychosis - Pipeline by Merck & Co., Inc., H2 2016
  • Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H2 2016
  • Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H2 2016
  • Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Psychosis - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Psychosis - Dormant Projects, H2 2016
  • Psychosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Psychosis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top